+44 1478 350008Cell & Developmental Biology : Citations & Metrics Report
Articles published in Cell & Developmental Biology have been cited by esteemed scholars and scientists all around the world. Cell & Developmental Biology has got h-index 15, which means every article in Cell & Developmental Biology has got 15 average citations.
Following are the list of articles that have cited the articles published in Cell & Developmental Biology.
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
Year wise published articles |
30 | 30 | 26 | 5 | 8 |
Year wise citations received |
123 | 142 | 124 | 118 | 105 |
| Journal total citations count | 951 |
| Journal impact factor | 5.1 |
| Journal 5 years impact factor | 6.8 |
| Journal cite score | 7.0 |
| Journal h-index | 15 |
| Journal h-index since 2018 | 12 |
Important citations (614)
Pashov a, hernandez puente cv, ibrahim sm, monzavi-karbassi b, makhoul i, kieber-emmons t. thinking cancer. monoclonal antibodies in immunodiagnosis and immunotherapy. 2018 jun 1;37(3):117-25. |
|
Chen y, zhang y, song w, zhang y, dong x, tan m. ginsenoside rh2 improves the cisplatin anti-tumor effect in lung adenocarcinoma a549 cells via superoxide and pd-l1. anti-cancer agents in medicinal chemistry (formerly current medicinal chemistry-anti-cancer agents). 2020 mar 1;20(4):495-503. |
|
Kalyanaraman b, cheng g, zielonka j, bennett b. low-temperature epr spectroscopy as a probe-free technique for monitoring oxidants formed in tumor cells and tissues: implications in drug resistance and oxphos-targeted therapies. cell biochemistry and biophysics. 2019 mar;77(1):89-98. |
|
Valle s, alcalá s, martin-hijano l, cabezas-sáinz p, navarro d, muñoz er, yuste l, tiwary k, walter k, ruiz-cañas l, alonso-nocelo m. exploiting oxidative phosphorylation to promote the stem and immunoevasive properties of pancreatic cancer stem cells. nature communications. 2020 oct 16;11(1):1-9. |
|
Chen x, chen s, yu d. metabolic reprogramming of chemoresistant cancer cells and the potential significance of metabolic regulation in the reversal of cancer chemoresistance. metabolites. 2020 jul;10(7):289. |
|
Xia x, zhou w, guo c, fu z, zhu l, li p, xu y, zheng l, zhang h, shan c, gao y. glutaminolysis mediated by malt1 protease activity facilitates pd-l1 expression on abc-dlbcl cells and contributes to their immune evasion. frontiers in oncology. 2018 dec 18;8:632. |
|
Kryczka j, kryczka j, czarnecka-chrebelska kh, brzezia?ska-lasota e. molecular mechanisms of chemoresistance induced by cisplatin in nsclc cancer therapy. international journal of molecular sciences. 2021 jan;22(16):8885. |
|
Fedorchuk o, susak y, rudyk m, senchylo n, khranovska n, skachkova o, skivka l. immunological hallmarks of cis-ddp-resistant lewis lung carcinoma cells. cancer chemotherapy and pharmacology. 2018 feb;81(2):373-85. |
|
Liu q, jiang l, li k, li h, lv g, lin j, qiu l. immuno-pet imaging of 68 ga-labeled nanobody nb109 for dynamic monitoring the pd-l1 expression in cancers. cancer immunology, immunotherapy. 2021 jun;70(6):1721-33. |
|
Nguyen hd, ticer t, bastian d, kuril s, li h, du h, yan c, yu xz. lysosomal acid lipase is required for donor t cells to induce graft-versus-host disease. cell reports. 2020 oct 27;33(4):108316. |
|
Klein k, he k, younes ai, barsoumian hb, chen d, ozgen t, mosaffa s, patel rr, gu m, novaes j, narayanan a. role of mitochondria in cancer immune evasion and potential therapeutic approaches. frontiers in immunology. 2020;11. |
|
Mirzaei s, hushmandi k, zabolian a, saleki h, torabi sm, ranjbar a, seyedsaleh s, sharifzadeh so, khan h, ashrafizadeh m, zarrabi a. elucidating role of reactive oxygen species (ros) in cisplatin chemotherapy: a focus on molecular pathways and possible therapeutic strategies. molecules. 2021 jan;26(8):2382. |
|
Yuan y, adam a, zhao c, chen h. recent advancements in the mechanisms underlying resistance to pd-1/pd-l1 blockade immunotherapy. cancers. 2021 jan;13(4):663. |
|
Mirzaei s, hushmandi k, zabolian a, saleki h, torabi sm, ranjbar a, seyedsaleh s, sharifzadeh so, khan h, ashrafizadeh m, zarrabi a. elucidating role of reactive oxygen species (ros) in cisplatin chemotherapy: a focus on molecular pathways and possible therapeutic strategies. molecules. 2021 jan;26(8):2382. |
|
Segovia-mendoza m, romero-garcia s, lemini c, prado-garcia h. determining factors in the therapeutic success of checkpoint immunotherapies against pd-l1 in breast cancer: a focus on epithelial-mesenchymal transition activation. journal of immunology research. 2021 jan 7;2021. |
|
Theodoropoulos g, albanis k, wangpaichitr m. perspective on the treatment of non-small cell lung cancer in the context of potential sars-cov-2 infection during the pandemic. journal of current science and technology. 2021 jan;11(1). |
|
Shi q, chen q, zhou z, zheng x, huang x, fang m, hu y, song l, yang h, chen q. hypoxia-induced antizyme inhibitors 2 regulates cisplatin resistance through epithelia-mesenchymal transition pathway in non-small cell lung cancer. pulmonary pharmacology & therapeutics. 2021 may 31: 102048. |
|
Yuan y, adam a, zhao c, chen h. recent advancements in the mechanisms underlying resistance to pd-1 / pd-l1 blockade immunotherapy. cancers 2021, 13, 663. |
|
Luna-yolba r, marmoiton j, gigo v, marechal x, boet e, sahal a, alet n, abramovich i, gottlieb e, visentin v, paillasse mr. disrupting mitochondrial electron transfer chain complex i decreases immune checkpoints in murine and human acute myeloid leukemic cells. cancers. 2021 jan; 13 (14): 3499. |
|
Cruz-bermúdez a, laza-briviesca r, casarrubios m, sierra-rodero b, provencio m. the role of metabolism in tumor immune evasion: novel approaches to improve immunotherapy. biomedicines. 2021 apr; 9 (4): 361. |
|